Professor Garret FitzGerald FRS


Professor of Medicine and Pharmacology, McNeil Professor in Translational Medicine and Therapeutics, Chair Department of Pharmacology, Director, Institute for Translational Medicine & Therapeutics, Perelman School of Medicine, University of Pennsylvania

Dr. FitzGerald's research has been characterized by an integrative approach to elucidating the mechanisms of drug action. He was the first to describe the dose dependent suppression by aspirin of thromboxane and prostacyclin biosynthesis in vivo. His work contributed substantially to the development of low-dose aspirin. FitzGerald's group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. Aside from this work, FitzGerald has also discovered many products of lipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has contributed substantially to our understanding of the importance of peripheral clocks in the regulation of cardiovascular and metabolic function.

Our mission

To recognise, promote, and support excellence in science and to encourage the development and use of science for the benefit of humanity.

Our priorities

  • Promoting science and its benefits
  • Recognising excellence in science
  • Supporting outstanding science
  • Providing scientific advice for policy
  • Fostering international and global cooperation
  • Education and public engagement